- Home
- PRVA vs APGE Comparison
PRVA vs APGE Comparison
Compare PRVA & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRVA | APGE |
|---|---|---|
| Founded | 2007 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 4.7B |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | PRVA | APGE |
|---|---|---|
| Price | $24.18 | $77.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | $30.46 | ★ $99.44 |
| AVG Volume (30 Days) | 679.3K | ★ 931.0K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.88 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $2,042,569,000.00 | N/A |
| Revenue This Year | $104.97 | N/A |
| Revenue Next Year | $9.92 | N/A |
| P/E Ratio | $172.26 | ★ N/A |
| Revenue Growth | ★ 19.01 | N/A |
| 52 Week Low | $18.77 | $26.20 |
| 52 Week High | $26.51 | $80.99 |
Technical Indicators
Market Signals| Indicator | PRVA | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 52.05 | 65.21 |
| Support Level | $23.34 | $73.55 |
| Resistance Level | $24.27 | $80.44 |
| Average True Range (ATR) | 0.71 | 3.12 |
| MACD | -0.01 | -0.53 |
| Stochastic Oscillator | 54.21 | 66.80 |
Price Performance
Historical ComparisonAbout PRVA Privia Health Group Inc.
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.